000111677 001__ 111677 000111677 005__ 20230519145608.0 000111677 0247_ $$2doi$$a10.3389/fonc.2021.695038 000111677 0248_ $$2sideral$$a127856 000111677 037__ $$aART-2021-127856 000111677 041__ $$aeng 000111677 100__ $$aJantus-Lewintre E. 000111677 245__ $$aProspective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study 000111677 260__ $$c2021 000111677 5060_ $$aAccess copy available to the general public$$fUnrestricted 000111677 5203_ $$aFinding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an unmet medical need. We explored a set of genetic variants in the VEGF-pathway as potential biomarkers to predict clinical outcomes of patients with non-small-cell lung cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the relationship between VEGF-pathway components with both pathological and prognostic variables in response to chemotherapy plus bevacizumab in 168 patients with non-squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and expression of specific endothelial surface markers and single-nucleotide polymorphisms in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-free survival. Secondary endpoints included overall survival and objective tumor response. VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p = 0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A rs833061 variant was found to be related with response to treatment, with 61.1% of patients harboring the CC allele achieving partial treatment response. High pre-treatment circulating levels of VEGF-A were associated with shorter progression-free survival (p = 0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A and plasma levels of VEGF-A were associated with clinical benefit, progression-free survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung cancer patients receiving chemotherapy plus antiangiogenic therapy. © Copyright © 2021 Jantus-Lewintre, Massutí Sureda, González Larriba, Rodríguez-Abreu, Juan, Blasco, Dómine, Provencio Pulla, Garde, Álvarez, Maestu, Pérez de Carrión, Artal, Rolfo, de Castro, Guillot, Oramas, de las Peñas, Ferrera, Martínez, Serra, Rosell and Camps. 000111677 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000111677 590__ $$a5.738$$b2021 000111677 592__ $$a1.291$$b2021 000111677 594__ $$a4.5$$b2021 000111677 591__ $$aONCOLOGY$$b78 / 245 = 0.318$$c2021$$dQ2$$eT1 000111677 593__ $$aOncology$$c2021$$dQ1 000111677 593__ $$aCancer Research$$c2021$$dQ1 000111677 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000111677 700__ $$aMassutí Sureda B. 000111677 700__ $$aGonzález Larriba J.L. 000111677 700__ $$aRodríguez-Abreu D. 000111677 700__ $$aJuan O. 000111677 700__ $$aBlasco A. 000111677 700__ $$aDómine M. 000111677 700__ $$aProvencio Pulla M. 000111677 700__ $$aGarde J. 000111677 700__ $$aÁlvarez R. 000111677 700__ $$aMaestu I. 000111677 700__ $$aPérez de Carrión R. 000111677 700__ $$0(orcid)0000-0002-3662-7660$$aArtal Cortés, Á.$$uUniversidad de Zaragoza 000111677 700__ $$aRolfo C. 000111677 700__ $$ade Castro J. 000111677 700__ $$aGuillot M. 000111677 700__ $$aOramas J. 000111677 700__ $$ade las Peñas R. 000111677 700__ $$aFerrera L. 000111677 700__ $$aMartínez N. 000111677 700__ $$aSerra Ò. 000111677 700__ $$aRosell R. 000111677 700__ $$aCamps C. 000111677 700__ $$aon behalf of Grupo Espanol de Cancer de Pulmon (GECP) 000111677 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000111677 773__ $$g11 (2021), 695038 [11 pp]$$pFront. oncol.$$tFrontiers in Oncology$$x2234-943X 000111677 8564_ $$s1120864$$uhttps://zaguan.unizar.es/record/111677/files/texto_completo.pdf$$yVersión publicada 000111677 8564_ $$s2813338$$uhttps://zaguan.unizar.es/record/111677/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000111677 909CO $$ooai:zaguan.unizar.es:111677$$particulos$$pdriver 000111677 951__ $$a2023-05-18-16:06:17 000111677 980__ $$aARTICLE